#CSNinAmerica Conference Hashtag
CSN in America
Wed 4th Nov 2015
Open date in Symplur Signals
The recent TEMPO trial suggests a role for tolvaptan use in the management of autosomal dominant polycystic kidney disease (ADPKD), and the drug has recently been approved for use in Canada. Many unanswered questions remain for the prescribing physician however, and with this debate, we will explore these unanswered questions.
#CSNinAmerica is a conference hashtag submitted by @CSNSCN
